Nektar Therapeutics Income Statement - Quarterly (NASDAQ:NKTR)

Add to My Stocks
$19.39 $0.53 (2.81%) NKTR stock closing price Apr 25, 2017 (Closing)

Fundamental analysis of NKTR stock involves analyzing its financial statements, apart from checking the Nektar Therapeutics stock price An income statement is one of the three key financial statements furnished by a company, the other two being the balance sheet and the cashflow statement. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has grown from $36.34M to $37.45M and how operating and non operating activities have impacted the NKTR stock. The Nektar Therapeutics profit and loss statement for 2016-Q4 shows a profit of $-42.2M. Profits have grown from $-43.22M QoQ. Apart from this an investor should also check Nektar Therapeutics assets and Nektar Therapeutics free cash flow. View details of revenue and profits for Nektar Therapeutics for latest & last 40 quarters.

show more
Annual
Quarterly
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3
Nektar Therapeutics Net Sales or Revenues
37.45M36.34M32.77M58.88M39.37M59.95M22.66M108.8M19.55M132.87M
Cost Of Goods Sold (COGS)6.61M7.03M7.7M8.87M8.37M6.76M10.53M8.44M6.31M9.22M
Nektar Therapeutics Gross Profit
30.85M29.3M25.06M50.01M31.02M53.19M12.12M100.35M13.26M123.65M
Research & Development Expense50.24M51.95M52.35M49.26M47.14M43.22M45.41M47.01M38.5M34.2M
Selling General & Admin Expense12.77M10.25M11.03M10.22M13.24M9.54M10.18M10.3M12.26M9.13M
Income Before Depreciation Depletion Amortization-32.15M-32.9M-38.32M-9.48M-29.36M0.41M-43.46M43.04M-37.49M80.32M
Depreciation Depletion Amortization----------
Non Operating Income0.73M0.33M0.45M0.87M-13.73M0.89M0.24M0.21M0.29M0.12M
Interest Expense10.35M10.51M10.6M10.72M10.99M9.42M9.27M9.22M9.62M9.59M
Nektar Therapeutics Pretax Income
-41.76M-43.08M-48.47M-19.33M-54.1M-8.11M-52.49M34.03M-46.82M70.85M
Provision for Income Taxes0.46M0.13M0.12M0.16M0.04M0.09M0.16M0.21M-1.13M0.24M
Minority Interest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-42.2M-43.22M-48.6M-19.5M-54.14M-8.2M-52.66M33.82M-45.68M70.61M
Extraordinary Items & Discontinued Operations----------
Nektar Therapeutics Net Income (Profit/Loss)
-42.2M-43.22M-48.6M-19.5M-54.14M-8.2M-52.66M33.82M-45.68M70.61M
Average Shares used to compute Diluted EPS149.07M137.09M136.35M135.79M134.17M132.63M131.64M135.67M129.33M132.18M
Average Shares used to compute Basic EPS149.07M137.09M136.35M135.79M134.17M132.63M131.64M131.36M129.33M127.5M
Income Before Nonrecurring Items-42.2M-43.22M-48.6M-19.5M-54.14M-8.2M-52.66M33.82M-45.68M70.61M
Income from Nonrecurring Items----------
Nektar Therapeutics Earnings Per Share Basic Net
-0.28-0.32-0.36-0.14-0.40-0.06-0.400.26-0.350.55
Nektar Therapeutics Earnings Per Share Diluted Net
-0.28-0.32-0.36-0.14-0.40-0.06-0.400.25-0.350.53
EPS Diluted Before Nonrecurring Items-0.28-0.32-0.36-0.14-0.40-0.06-0.400.25-0.350.53
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common----------
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Income statement for another ticker

1:22
NKTR
Nektar Therapeutics stock analysis involves checking at least a few of the important things like:
  • Revenue: This is the inflow that is generated from the sale of goods or services and is $37.45M for this quarter of 2016-Q4. Our Nektar Therapeutics revenue chart gives a clear visual representation of how the topline growth has been. Investors often invest in only those companies where the revenue is growing at a steady rate.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-42.2M for Nektar Therapeutics for 2016-Q4. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.
The income statement is also called statement of revenue and expense. The financials along with Nektar Therapeutics historical stock prices provides a lot of details about the firm. .

Nektar Therapeutics Income Statement - Key Financial Ratios

PS ratio (
price sales ratio
)
17.4714
Operating margin
-85.8
Net profit margin
-112.7
Dividend yield
0%